Table 3.

Distribution of the properties of the study population according to the development of contrast nephropathy

	Patients who did not develop contrast nephropathy (n=228)	Patients who developed contrast nephropathy (n=19)	P
Age, years	59±10	65±11	0.008
Height, cm	165.00	164.00	0.370
	(160.00-170.00)	(157.00-169.00)
Weight, kg	80.00	80.00	0.767
	(71.25-88.75)	(71.00-87.00)
Body mass index, kg/m2	29.40	29.10	0.798
	(26.20-32.67)	(25-33.10)
Ejection fraction, %	60.00	52.00	0.089
	(50.00-65.00)	(50.00-62.00)
Mehran risk score	3.00	5.00	0.072
	(1.00-5.75)	(1.00-7.00)
Contrast dosage, mL	90.00	100.00	0.103
	(80.00-120.00)	(80.00-240.00)
Creatinine clearance, mL/min	91.76±23.52	86.57±22.92	0.356
Basal creatinine, mg/dL	0.79	0.85	0.054
	(0.70-0.92)	(0.80-1.09)
Glucose, mg/dL	100.50	101.00	0.790
	(91.25-128.00)	(95.00-132.00)
High density lipoprotein, mg/dL	41.00	38.00	0.305
	(34.25-48.00)	(34.00-40.00)
Low density lipoprotein, mg/dL	116.91±35.22	111.89±41.45	0.557
Tryglyceride, mg/dL	143.00	154.00	0.780
	(99.00-200.50)	(107.00-172.00)
Hemoglobin, g/dL	13.02±1.71	12.76±1.26	0.524
Waist circumference, cm	102.00	102.00	0.534
	(94.00-112.00)	(84.00-114.00)
Gensini score	5 (0-22)	24 (6-64.5)	0.020
Male gender, n (%)	118 (51.8)	12 (63.2)	0.473
Diabetes, n (%)	65 (28.5)	8 (42.1)	0.324
Hypertension, n (%)	145 (63.6)	12 (63.2)	1.00
Hyperlipidemia, n (%)	65 (28.5)	7 (36.8)	0.613

^*Control group is different from the nebivolol and carvedilol groups.

^†There is a statistically significant difference between the control and nebivolol groups.

^‡Carvedilol group is different from the control and metoprolol groups.

^§Metoprolol and nebivolol groups are different.

The percentage, mean or median values were accepted to be statistically significantly different where p<0.05